Crossject is up 10%, following the extension of the geographical coverage of its December 2023 marketing agreement with an undisclosed partner for its emergency epileptic seizure treatment, Zepizure.

Thanks to this extension, the contract now covers a total of 11 European countries. As a reminder, Crossject will receive milestone payments of up to one million euros, as soon as marketing authorizations are obtained in the territories concerned.

Crossject will sell Zepizure to its partner with a coefficient corresponding to a share of the gross margin. The company covers the costs of regulatory development and holds potential marketing authorizations.

Copyright (c) 2024 CercleFinance.com. All rights reserved.